Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism by Steffel, Jan & Braunwald, Eugene








Novel oral anticoagulants: focus on stroke prevention and treatment of
venous thrombo-embolism
Steffel, Jan; Braunwald, Eugene
Abstract: Anticoagulation for the long-term treatment and prevention of thrombo-embolic diseases as
well as for stroke prevention in atrial fibrillation (AF) has been accomplished by vitamin K antagonists for
the last half century. Although effective under optimal conditions, the imminent risk of a recurrent event
vs. the risk of bleeding due to the narrow therapeutic window, numerous food- and drug interactions,
and the need for regular monitoring complicate the long-term use of these drugs and render treatment
with these agents complicated. As a result, novel anticoagulants which selectively block key factors in
the coagulation cascade are being developed. The efficacy and safety of the direct thrombin inhibitor
dabigatran etexilate, as well as of the selective factor Xa inhibitors rivaroxaban and apixaban, have been
demonstrated in Phase III trials for stroke prevention in AF and the treatment and secondary prophylaxis
of venous thrombo-embolism. This review summarizes the results from recently published pivotal clinical
trials and discusses the opportunities as well as uncertainties in the clinical applications of these novel
agents
DOI: https://doi.org/10.1093/eurheartj/ehr052





Steffel, Jan; Braunwald, Eugene (2011). Novel oral anticoagulants: focus on stroke prevention and




Novel oral anticoagulants: focus on
stroke prevention and treatment of venous
thrombo-embolism
Jan Steffel1,2* and Eugene Braunwald3
1Department of Cardiology, CardioVascular Center, University Hospital Zurich, Ra¨mistrasse 100, CH-8091 Zurich, Switzerland; 2Cardiovascular Research, Institute of Physiology,
University of Zurich, Zurich, Switzerland; and 3TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School,
Boston, MA, USA
Received 24 December 2010; revised 24 January 2011; accepted 4 February 2011; online publish-ahead-of-print 18 March 2011
Anticoagulation for the long-term treatment and prevention of thrombo-embolic diseases as well as for stroke prevention in atrial fibrillation
(AF) has been accomplished by vitamin K antagonists for the last half century. Although effective under optimal conditions, the imminent risk
of a recurrent event vs. the risk of bleeding due to the narrow therapeutic window, numerous food- and drug interactions, and the need for
regular monitoring complicate the long-term use of these drugs and render treatment with these agents complicated. As a result, novel antic-
oagulants which selectively block key factors in the coagulation cascade are being developed. The efficacy and safety of the direct thrombin
inhibitor dabigatran etexilate, as well as of the selective factor Xa inhibitors rivaroxaban and apixaban, have been demonstrated in Phase III
trials for stroke prevention in AF and the treatment and secondary prophylaxis of venous thrombo-embolism. This review summarizes the
results from recently published pivotal clinical trials and discusses the opportunities as well as uncertainties in the clinical applications of these
novel agents.
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Introduction
Activation of the plasma coagulation cascade is central to throm-
bus formation in the ‘low pressure’ segment of the circulation,
including the venous system and left atrium (Figure 1).1,2 Anticoa-
gulation for the long-term treatment and prophylaxis of
thrombo-embolic diseases as well as for stroke prevention in
atrial fibrillation (AF) is accomplished by vitamin K antagonists
(VKAs). The latter are very effective under optimal conditions, in
which a stable level of anticoagulation can be obtained.3,4 The dif-
ficulty, however, of achieving such optimal conditions is not infre-
quently problematic since various foods, especially vegetables, may
significantly alter both the pharmacokinetics and pharmacody-
namics of VKAs.5 Furthermore, numerous drugs, in particular indu-
cers and inhibitors of hepatic P450 isoenzymes that metabolize
VKAs, are notorious for unpredictably increasing or decreasing
the anticoagulant effects of these drugs.5– 7 As such, the long-term
use of VKAs is frequently problematic due to their narrow thera-
peutic window, requiring tedious life-long coagulation monitoring,
and careful drug dosing.8 Indeed, the risk of bleeding (in the case of
excessive anticoagulation) as well as the risk of a recurrent throm-
botic event (in the case of insufficient anticoagulation) are perti-
nent and constant threats in the management of these patients.9
As a result of these limitations, several novel agents have been
developed to replace VKAs.10 In contrast to the latter, which
block the synthesis of the inactive forms of vitamin K-dependent
coagulation factors II, VII, IX, and X, these novel agents inhibit
selectively the active form of a single factor of the coagulation
cascade (Figure 1). Out of the numerous classes of new drugs,
factor Xa (FXa) blockers and direct thrombin inhibitors have
been most successfully studied in various indications. This review
focuses on the most recent trials investigating these substances
for stroke prevention in AF and for the treatment of venous
thrombo-embolic (VTE) disorders (Table 1).
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Table 1 Overview over the most important Phase III randomized controlled trials involving the
substances discussed in the text
Green, met pre-defined endpoint; red, did not meet pre-defined endpoint or was terminated early due to safety concerns (APPRAISE-2); black, ongoing.
See text for details.
Figure 1 Point of action of novel oral anticoagulants in the coagulation cascade.
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Direct thrombin inhibitors
Direct thrombin (factor IIa) inhibitors selectively block the activity
of thrombin both in solution as well as in its fibrin-bound state,
thus preventing both the amplifying auto-feedback activation of
the coagulation cascade as well as the conversion of fibrinogen
to fibrin (Figure 1).
Dabigatran etexilate
Dabigatran etexilate (Pradaxaw) is absorbed as a prodrug with a
bioavailability of 6%. It is subsequently converted into its active
form by circulating esterases.11,12 Elimination is 80% renal, which
has to be taken into account when the drug is given to patients
with impaired renal function. Its half-life is 14–17 h, and it is
given twice daily.11
Atrial fibrillation
In the landmark Randomized Evaluation of Long Term Anticoagu-
lant Therapy (RE-LY) trial, 18 113 patients with AF and at least one
additional risk factor for stroke were randomized in a partial
PROBE design (Prospective Randomized Open Trial with Blinded
Adjudication of Events) to receive dabigatran 110 mg bid, dabiga-
tran 150 mg bid, or an adjusted dose of warfarin to an INR of
2.0–3.0.13,14 After a mean follow-up of 2 years, both doses of dabi-
gatran proved non-inferior to warfarin; the primary endpoint,
stroke or systemic embolism, occurred at 1.69%/year with warfarin
as compared to 1.53%/year with dabigatran 110 mg bid [relative
risk (RR) 0.91; 95% confidence interval (CI) 0.74–1.11] and
1.11%/year with dabigatran 150 mg bid (RR 0.66; 0.53–0.82;
Figure 2). Major bleeding rates were similar among patients on war-
farin (3.36%/year) and those on dabigatran 150 mg bid (3.11%/year,
P ¼ 0.31), while bleeding was less frequent in patients on the low
dose of dabigatran (2.71%/year, P ¼ 0.003 for dabigatran 110 mg
bid vs. warfarin). Haemorrhagic strokes were less frequent with
both dabigatran doses compared with warfarin, occurring at
0.38%/year in warfarin-treated patients as compared to 0.12%/
year (P, 0.001) and 0.10%/year (P, 0.001) in patients on 110
and 150 mg bid dabigatran, respectively. In contrast, gastrointesti-
nal bleeding was more frequent with dabigatran 150 mg bid
(1.51%/year) when compared with warfarin (1.02%/year, P,
0.001), whereas it was not statistically different between warfarin
and dabigatran 110 mg bid. Finally, dabigatran 150 mg bid fell just
short of reducing the most important endpoint, all-cause mortality
(3.6 vs. 4.1%/year with warfarin, P ¼ 0.051), further substantiating
the beneficial overall effect of this agent.
In the original analysis of the data, an increase in the risk of myo-
cardial infarction was observed with both doses of dabigatran.13 A
recent comprehensive analysis of patients’ ECGs, however, ident-
ified 28 silent myocardial infarctions, which were not included in
the original analysis. When these additional events were included
in the data, no statistically significant increase in myocardial infarc-
tion was observed with the 110 mg [hazard ratio (HR) 1.29; 95%
CI 0.96–1.75; P ¼ 0.09] and the 150 mg doses of dabigatran (HR
1.27; 95% CI 0.94–1.71; P ¼ 0.12) when compared with warfarin.14
In the RE-LY trial, dyspepsia was more common with dabigatran
110 mg bis (11.8%) and 150 mg bis (11.3%) when compared with
warfarin (5.8%), which most likely contributed to a more frequent
rate of study drug discontinuation after 2 years (21, 21, and 17%
for dabigatran 110 mg, dabigatran 150 mg, and warfarin, respect-
ively). Importantly, and in contrast to the experience with ximela-
gatran,15 no elevation in liver enzymes was observed with either of
the dabigatran doses in RE-LY (2.1 vs. 1.9 vs. 2.2% in patients on
dabigatran 110 mg, dabigatran 150 mg, and warfarin, respect-
ively).13 Results from subgroup analyses from RE-LY were similar
Figure 2 Cumulative hazard rates for the primary outcome of stroke or systemic embolism in the RE-LY study, according to Treatment
Group. Reproduced with permission from Connolly et al.13
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to those of the total population, confirming its findings in the sub-
group of patients with a prior stroke16, in patients with different
CHADS2 scores,
17 as well as in patients undergoing cardiover-
sion.18 When comparing dabigatran with different average levels
of INR control in the warfarin population, patients in centres
with the poorest INR control appeared to profit most in terms
of stroke prevention (although no statistically significant interaction
was observed).19 Similarly, no difference in time to major bleeding
or intracranial bleeding was seen across different INR strata,19 indi-
cating a favourable efficacy and safety profile of the drug across all
strata of INR control.
As a result of these robust data, the FDA has approved dabiga-
tran 150 mg bid for stroke prevention in atrial fibrillation. Further-
more, the American College of Cardiology Foundation, American
Heart Association and Heart Rhythm Society has very recently
given a Class I / level of evidence B recommendation for anticoa-
gulant treatment of these patients with dabigatran.20 In contrast,
the 110 mg bid dose did not gain approval. Although reduced
bleeding rates were observed with the 110 mg dose, the similar
stroke rate when compared with warfarin as well as post hoc ana-
lyses showing superiority of dabigatran 150 mg bid over 110 mg bid
led the FDA to deny approval of the latter regimen. In contrast, to
the surprise of many, a reduced dosing regimen (dabigatran 75 mg
bid) was approved for patients with renal insufficiency (as defined
by a creatinine clearance of 15–30 mL/min). This dose was not
studied in the RE-LY trial and was approved based on pharmaco-
kinetic data from other dabigatran trials to enable the treatment
of patients with severe renal insufficiency.
Venous thrombo-embolism
Dabigatran etexilate has been approved by the EMEA for the pre-
vention of VTE events in patients undergoing elective total hip or
knee replacement, based mainly on the results from the
RE-NOVATE and RE–MODEL trials.21 –24
In the Phase III RE-COVER trial, dabigatran etexilate 150 mg bid
was compared with INR-adjusted warfarin for 6 months in the
treatment of an acute VTE.25 Recurrent VTE occurred in 2.4% of
the patients on dabigatran as compared to 2.1% on warfarin (P
, 0.001 for non-inferiority), with an HR of 1.10 for dabigatran
(0.65–1.84). Overall bleeding was more frequent in warfarin-
treated patients [21.9 vs. 16.1%, HR with dabigatran 0.71 (0.59–
0.85); P, 0.001], whereas major bleeding was similar in the two
study groups (1.6 and 1.9% for dabigatran and warfarin, respect-
ively). As in RE-LY, dyspepsia was more frequent with dabigatran.
These results indicate that fixed-dose dabigatran etexilate is as
effective and safe as INR-adjusted warfarin for the treatment of
acute VTEs.
A second VTE treatment study (RE-COVER II, NCT00680186)
is currently ongoing. Furthermore, two trials are underway for
the secondary prevention of VTE following successful treatment
with warfarin for 3–6 months (RE–MEDY, NCT00329238) or
6–18 months (NCT00558259) after an acute symptomatic VTE
event.
Acute coronary syndromes
For secondary prevention after an acute coronary syndrome
(ACS), the placebo-controlled Phase II RE-DEEM trial26 revealed
a dose-dependent increase in bleeding events, but showed an
overall acceptable safety profile of dabigatran on top of dual anti-
platelet therapy with major and clinically relevant minor bleeding
rates ,2%. A Phase III study for this indication, however, has
not yet been initiated, most likely due to the inherent threat of
excess major haemorrhage with ‘triple anticoagulation’ (as it has
been observed in the APPRAISE-2 trial with apixaban).
Factor Xa inhibitors
Factor Xa inhibitors exert an anticoagulant effect by blocking the
generation of thrombin from prothrombin. They are divided into
‘direct’ and ‘indirect’ inhibitors, the latter blocking FXa via its
physiologic inhibitor antithrombin.10,27– 33 Oral direct Xa inhibitors
such as rivaroxaban, apixaban and edoxaban are furthest advanced
in the development for stroke prevention in AF and treatment of
VTE.
Rivaroxaban
Rivaroxaban (Xareltow) is an oral FXa inhibitor that blocks FXa
both in its free and prothrombin-bound states.34 It has a half-life
of 7–11 h requiring once- or twice-daily dosing, and a dual
mode of elimination, with two-thirds of the drug being metab-
olized by the liver and one-third eliminated unchanged by the
kidneys.35 As a result, rivaroxaban is contraindicated in patients
with a clinically relevant bleeding risk as well as in patients with
liver disease associated with coagulopathy, and care should be
taken when using it in patients with impaired renal function.
Atrial fibrillation
In the Phase III, double-blind, double-dummy ‘Rivaroxaban
Once-daily oral direct FXa inhibition Compared with vitamin K
antagonism for prevention of stroke and Embolism Trial in Atrial
Fibrillation’ (ROCKET AF) study, rivaroxaban 20 mg once daily
(15 mg daily for patients with creatinine clearance 30–45 ml/
min) was compared with INR-adjusted warfarin for stroke preven-
tion in 14 264 patients with AF. In contrast to the RE-LY trial with
dabigatran which was not blinded (see above), ROCKET AF was
double blinded. The results, presented at the American Heart
Association Meeting 201036 demonstrated non-inferiority of
rivaroxaban when compared with warfarin (HR 0.79; 95% CI
0.66–0.96; P, 0.001) with event rates of 1.71 and 2.16%/year,
respectively. Furthermore, rivaroxaban was superior to warfarin
in the ‘on treatment’ analysis (P ¼ 0.013). However, in the
intention-to-treat analysis, statistical superiority was not observed
with event rates of 2.12 and 2.42%/year with rivaroxaban and war-
farin, respectively (HR 0.88; 95% CI 0.74–1.03; P ¼ 0.117). Most
likely, the long period during which events were included of the
analysis after drug discontinuation in the intention-to-treat analysis
resulted in a significant degree of regression to the mean of the
results, leading to non-superiority of rivaroxaban in this analysis.
No difference between rivaroxaban and INR-adjusted warfarin
was observed in the rate of major and non-major clinically relevant
bleeding (HR 1.03; 95% CI 0.96–1.11; P ¼ 0.442). Although epi-
staxis as well as bleeding requiring transfusion were more
common with rivaroxaban (HR 1.25, 95% CI 1.01–1.55), the
most serious forms of haemorrhage, i.e. fatal bleeding (HR 0.50;
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95% CI 0.31–0.79; P ¼ 0.003) and intracranial haemorrhage (HR
0.67; 95% CI 0.47–0.94; P ¼ 0.019), were less common than
with warfarin. Also, haemorrhagic stroke was less frequently
observed with rivaroxaban (HR 0.59; 95% CI 0.37–0.93). Finally,
a trend towards a reduction in all-cause mortality (HR 0.85; 95%
CI 0.70–1.02) was observed with rivaroxaban in the on-treatment
analysis.
There was no difference in other side effects, including serious
adverse events, acute myocardial infarction, and liver enzyme
elevations. The main results of ROCKET AF were consistent
across pre-specified subgroups including patients with renal insuf-
ficiency, different CHADS2 scores, prior warfarin use, centre
time in therapeutic range, and prior stroke.36 Publication of the
final results is anticipated for Spring 2011.
Venous thrombo-embolism
In the European Union and several other countries worldwide
(although not in the USA), rivaroxaban has been approved for
the prevention of VTE in adult patients undergoing elective hip or
knee replacement due to the convincing results of the ‘REgulation
of Coagulation in major Orthopaedic surgery reducing the Risk of
Deep vein thrombosis and pulmonary embolism’ (RECORD) study
programme.37– 41 A Phase III study for the prevention of VTE in
medically ill patients including 8000 subjects is currently
ongoing (MAGELLAN, NCT00571649).
In the Phase III EINSTEIN-DVT study, 3449 patients received
either rivaroxaban or a VKA for the treatment of deep vein throm-
bosis.42 Initial treatment for 3 weeks with a high dose of rivarox-
aban (15 mg bid) followed by 20 mg once daily was compared
with initial treatment with subcutaneous enoxaparin or fondapar-
inux followed by a VKA for 3, 6, or 12 months (individual treat-
ment duration was according to the treating physician’s
discretion). The primary endpoint, first symptomatic VTE,
occurred in 36 patients (2.1%) on rivaroxaban as compared to
51 patients (3.0%) in the conventional treatment arm [HR 0.68
(95% CI 0.44–1.04), P, 0.0001 for non-inferiority and P ¼
0.076 for superiority of rivaroxaban; Figure 3A]. Bleeding was
similar in both groups with 139 (8.1%) and 138 (8.1%) of the
patients on rivaroxaban and on the conventional regimen, respect-
ively, experiencing first major bleeding or clinically relevant non-
major bleeding (HR 0.97; 0.76–1.22; P ¼ 0.77).
Both efficacy and safety outcomes were consistent across all
subgroups. Fifty-one patients (2.9%) in the rivaroxaban group
and 73 (4.2%) in the conventional treatment group reached the
net clinical benefit endpoint defined as the primary efficacy
outcome + major bleeding, indicating the superiority of rivaroxa-
ban over enoxaparin followed by a VKA for this secondary
Figure 3 The Kaplan–Meier cumulative event rates for the primary efficacy outcome in EINSTEIN-DVT (A) and EINSTEIN-Ext (B).42 VKA,
vitamin K antagonist. Reproduced with permission from Buller et al.42
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endpoint (HR 0.67; 95% CI 0.47–0.95; P ¼ 0.03). Total mortality
occurred in 38 (2.2%) and 49 (2.9%) of the patients on rivaroxaban
and on the conventional regimen, respectively (HR 0.67; 95% CI
0.44–1.02; P ¼ 0.06), clearly indicating non-inferiority but falling
just short of superiority of rivaroxaban.
Taken together, these results demonstrate that rivaroxaban is at
least as effective as enoxaparin/fondaparinux followed by a VKA
for the treatment of DVT with a similar risk of bleeding.
EINSTEIN-DVT’s sister study, EINSTEIN-PE (NCT00439777),
investigating rivaroxaban for the treatment of pulmonary embolism
in a very similar study design is expected to be completed by the
middle of 2011.
The EINSTEIN-Extension study, performed in parallel to EIN-
STEIN DVT and included in the same publication,42 was designed
to assess the efficacy and safety of rivaroxaban for prevention of sec-
ondary VTE. According to the current guidelines, the initial treat-
ment duration for acute VTE depends on the presumed
aetiology of the event; however, the optimal duration of treatment
is still debated.8 Therefore, EINSTEIN-Extension included patients,
who according to their treating physician’s decision, had completed
their designated duration of anticoagulation (6–12 months) for an
acute episode of VTE. Importantly, patients with an indication for
longer anticoagulation (e.g. cancer-related VTE) were excluded
from the trial. A total of 1197 patients were recruited both from
the EINSTEIN-DVT and EINSTEIN-PE cohorts as well as from
patients independently treated with a VKA for symptomatic VTE.
After a mean treatment duration of 190 days, symptomatic recur-
rent VTE events were reduced by 82% with rivaroxaban as com-
pared to placebo (HR 0.18; P, 0.0001; Figure 3B) with similar
bleedings rates.42 These impressive results not only demonstrated
efficacy and safety of rivaroxaban in the secondary prevention of
VTE, but also challenge the current guidelines with respect to
the optimal treatment duration in these patients.
Acute coronary syndrome
In the Phase II randomized, double-blind, placebo-controlled, dose-
finding ATLAS-1 TIMI 46 trial of patients with a recent ACS,43 riv-
aroxaban increased the risk of clinically significant bleeding in a
dose-dependent manner when compared with placebo (P,
0.0001), while leading to a (non-significant) relative reduction in
the primary composite efficacy endpoint of death, MI, stroke, or
severe recurrent ischaemia requiring revascularization (5.6 vs. 7
0%, P ¼ 0.10). As a result, a Phase III randomized, double-blind,
placebo-controlled trial (ATLAS ACS TIMI 51, NCT00809965) is
comparing two doses of rivaroxaban (2.5 and 5 mg bid) with
placebo in patients with ACS who are receiving standard antiplate-
let therapy with aspirin and clopidogrel or aspirin alone. Enrolment
has been completed, and it is expected that the results will be
available in late 2011.44
Apixaban
The oral direct FXa inhibitor apixaban inhibits both free and
prothrombin-bound FXa.45,46 It is partly metabolized via the
CYP3A4 pathway and eliminated largely via the faecal route
(70%),47 which may prove to reduce its risk in patients with
impaired renal function.
Atrial fibrillation
Preliminary results of the Phase III, double-blind, randomized,
AVERROES trial (NCT00496769) were recently published.
Patients with AF and at least one additional risk factor, who had
either used and discontinued a VKA (40%) or who were expected
to be unsuitable for treatment with a VKA (60%), were random-
ized to receive either aspirin (81–324 mg/day) or apixaban (5 mg
bid or, in selected patients, 2.5 mg bid). The average patient age
was 70 years, and the mean CHADS2 risk score was 2.1 in both
groups. At the first planned interim analysis of efficacy, the data
monitoring committee recommended early study termination for
compelling evidence of efficacy. After a median follow-up of 1
year, the incidence of stroke or systemic embolism occurred in
52 patients (1.6%/year) and 113 patients (3.7%/year) in the
apixaban and aspirin groups, respectively (HR 0.45; 95% CI
0.32–0.62; P, 0.001). This was not entirely unexpected since it
is well established that VKA is superior to aspirin in protecting
patients with AF from the development of a thrombo-embolic
stroke. Although major bleeding (1.4 vs. 1.2%/year for apixaban
and aspirin, respectively, P ¼ 0.57), intracranial bleeding (0.4 vs.
0.4%, P ¼ 0.69), and fatal bleeding (0.1% in both groups, P ¼
0.53) were similar between the two study arms, minor bleeding
was more common with apixaban (6.3 vs. 5.0%, P ¼ 0.05).
Furthermore, a trend towards a reduction in the secondary end-
point of overall mortality was observed with apixaban (110
patients, 3.5%/year) vs. aspirin (139 patients, 4.4%/year; HR 0.79
(0.62–1.02), P ¼ 0.07]. These results indicate a favourable profile
for apixaban when compared with aspirin in patients with AF
unsuitable for VKA treatment. As a consequence, aspirin use is
likely to be replaced in many of such patients with a novel
anticoagulant.
However, in order to have an impact on the current guidelines
and allow for a change in daily clinical practice, ‘unsuitability’
for VKA treatment needs to be clearly defined. Results of the
ARISTOTLE Phase III trial, in which 18 000 patients with AF
have been randomized to receive either apixaban 5 mg bid or a
VKA, are eagerly awaited;48 study completion is anticipated for
the Spring of 2011, with presentation at the ESC meeting in 2011.
Venous thrombo-embolism
Apixaban has been studied extensively for the prevention of VTE
in patients undergoing orthopaedic surgery in the ‘Apixaban
Dosed Orally Versus Anticoagulation with Injectable Enoxaparin
to Prevent Venous Thromboembolism’ (ADVANCE) study pro-
gramme, although with partly conflicting results.49–52
A Phase II trial for the treatment of symptomatic DVT reported
a favourable efficacy and safety profile for all doses of apixaban
when compared with low-molecular-weight heparin followed by
warfarin.53 In the ongoing Phase III AMPLIFY trial, initial treatment
with apixaban 10 mg twice daily for 7 days followed by 5 mg twice
daily is being compared with initial treatment with enoxaparin fol-
lowed by a VKA for 6 months for the treatment of acute DVT and
pulmonary embolism (NCT00643201). The Phase III double-blind
AMPLIFY-EXTENSION trial (NCT00633893) is comparing
apixaban (2.5 or 5 mg twice daily) and placebo in the secondary
prevention in patients with VTE who have completed 6- to
12-month treatment with apixaban or VKA.
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The Phase III double-blind double-dummy ADOPT trial compar-
ing extended treatment with apixaban 2.5 mg twice daily for 30
days with enoxaparin 40 mg once daily for at least 7 days followed
by placebo for the prevention of VTE in medically ill patients is
ongoing (NCT00457002).
Acute coronary syndrome
Apixaban was studied for secondary prevention after ACS [non-ST
elevation myocardial infarction (STEMI) or STEMI] in the Phase II
double-blind, placebo-controlled, dose-ranging APPRAISE trial.54
A dose-dependent increase in the risk of major or clinically rel-
evant non-major bleeding was observed. A reduction in ischaemic
events was also seen, but the trial was not powered to assess effi-
cacy endpoints with confidence. The follow-up Phase III
APPRAISE-2 trial (NCT00831441), comparing 5 mg bid apixaban
vs. placebo in post-ACS patients who were receiving aspirin and
clopidogrel (or aspirin only in a subgroup of patients), has recently
been stopped on the recommendation of the data safety monitor-
ing committee because of excessive bleeding and lack of efficacy.
Edoxaban
The free base of DU-176b, edoxaban, is a reversible direct inhibi-
tor of FXa, which is rapidly absorbed with good bioavailability,
a half-life of 8–10 h, and elimination largely via the kidneys.55 A
Phase III study comparing edoxaban with warfarin (after initial
treatment with heparin in both arms) (NCT00986154) for the
treatment of VTE disease is currently underway.
Atrial fibrillation
In the Phase II study for stroke prevention in AF (NCT00504556),
once-daily dosing of either 30 or 60 mg of edoxaban was associ-
ated with less bleeding than the respective twice-daily dosing regi-
mens.56 A large randomized, double-blind, double-dummy Phase III
trial (ENGAGE AF TIMI 48, NCT00781391) is being conducted
comparing two doses of edoxaban (30 and 60 mg once daily)
with INR-adjusted warfarin.57 The trial design allows for a dose
reduction in edoxaban-treated patients deemed to be at an
increased risk of bleeding based on anticipated drug exposure
levels and risk factors. Thus, this Phase III trial is the first to
study three doses of a Factor X inhibitor (60, 30, and 15 mg, the
latter in patients assigned to 30 mg and adjusted downwards).
Enrolment has been completed with 21 107 patients, and trial
completion is scheduled for mid-2012.
Implications and conclusions
Several novel, orally active anticoagulants have now been success-
fully tested against standard therapy with VKAs in the treatment
and prevention of VTE as well as for stroke prevention in patients
with AF. Studies with the direct thrombin inhibitor dabigatran
etexilate as well as the FXa inhibitors rivaroxaban and apixaban
are furthest advanced; indeed, rivaroxaban is approved for VTE
prevention in orthopaedic patients in many countries (albeit not
in the USA), whereas dabigatran has recently been approved for
stroke prevention in AF in the USA. When compared with
VKAs, these drugs possess a number of the desired properties
of an ‘ideal’ anticoagulant (Table 2), including enhanced safety
and efficacy profiles, oral bioavailability, and no requirement for
routine coagulation monitoring—all of which are particularly
attractive in the long-term use in stroke or VTE prevention. As a
result, broad-based application of these agents may substantially
increase the number of patients on adequate anticoagulation,
many of whom are not receiving such therapy due to the inconve-
nience and drawbacks of VKA treatment.58 Furthermore, the
favourable risk–benefit profile of these agents may have a substan-
tial impact on current guidelines, resulting in a significant increase
in the number of patients with a treatment indication as well as
in a prolongation of treatment duration (in the case of VTE). A
third potential application is to add the novel anticoagulant to
the antiplatelet regimen in the secondary prevention of patients
with ACS. Vitamin K antagonists are usually not administered to
such patients, unless a clear indication such as AF or VTE is
present.
In spite of the enthusiasm associated with the chance of repla-
cing warfarin for its present indications, some uncertainties remain.
Lack of coagulation monitoring: friend
or foe?
One of the greatest advantages of these novel agents in long-term
treatment is the lack of need for routine monitoring of coagulation.
Pharmacokinetic and Phase II studies with dabigatran and the three
anti-Xa agents discussed above (rivaroxaban, apixaban, and edox-
aban) have demonstrated drug levels and treatment effects inde-
pendent of most concomitant medication and food intake.
Furthermore, data from several Phase III trials have indicated that
this approach appears to be safe and effective for the studied indi-
cations. Indeed, it may be possible that for each drug, one (or two)
doses will be suitable for a large majority of patients. However,
without appropriate means of controlling treatment intensity,
safety and efficacy of application of these novel agents for long-
term care of patients with multiple co-morbidities, intercurrent ill-
nesses and receiving multiple medications, will require large obser-
vational studies. Since both overtreatment and undertreatment
may lead to serious sequelae, some monitoring of the intensity
of anticoagulation may be desirable both from an efficacy and
safety standpoint. The latter is especially true in view of the fact
that none of the novel anticoagulants has a specific antidote,
which may complicate treatment, especially in patients at an
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increased bleeding risk. Some recent efforts, however, have
reported on the development of an antidote for anti-Xa drugs.59,60
Several studies have recently been initiated with the goal of
establishing the parameter (activated partial thromboplastin time,
anti-FXa activity, INR, drug level) and target range for monitoring
of these agents.45,61– 66 However, these investigations are relatively
small and lack correlation of the anticoagulant markers with hard
clinical endpoints, an important prerequisite to assess their wide-
spread adoption. Hence, both the question of the desirability for
monitoring and the appropriate variables to be monitored
remain unclear at present.
Which patient needs to be switched
from vitamin K antagonists?
Several lines of evidence indicate that a large proportion of
patients will likely benefit from being switched from VKAs to
one of the novel anticoagulants. Most data supporting this
approach currently stem from the RE-LY trial, in which a consistent
signal for efficacy without an increase in bleeding was reported for
the 150 mg dose across all subgroups, including older patients,
patients with different CHADS2 scores, prior warfarin use, or
prior stroke.13,16,17,19 In relative terms, patients least likely to
derive an incremental benefit from being switched from a VKA
to dabigatran are those who are well controlled on warfarin
with INR values consistently in the target range. However, even
these patients would benefit from a reduced probability for intra-
cranial bleeding, which seems to occur less when compared with
VKAs. Conversely, patients with poor medication adherence are
notoriously difficult to treat with VKAs. However, it is unlikely
that their management will be greatly improved with novel anticoa-
gulants with short half-lives requiring twice-daily dosing.
Since VKAs are usually administered for a limited duration in the
treatment and prevention of DVT, switching to a novel anticoagu-
lant during the ongoing course of therapy does not appear war-
ranted for the majority of these patients. However, results from
the EINSTEIN-Extension trial indicate that switching to rivaroxa-
ban and prolonging the duration of treatment may be indicated
in patients for the secondary prevention of DVT.42 This benefit
is likely to be seen with the other novel anticoagulants as well.
Which drug for which patient?
With several novel agents becoming available for stroke prevention
in AF in the near future, it will be of great interest to assess which
group of patients will profit most with these new agents. The
recent results of the ROCKET AF trial36 have sparked considerable
debate on whether rivaroxaban may be as effective as dabigatran,
given that superiority was only reached in the on-treatment, but
not in the intention-to-treat analysis of the former. Valid cross-trial
comparisons, however, are impossible to perform in view of the
different study designs and the different patient populations
studied. Indeed, although superiority was shown for the higher
dose of dabigatran in the intention-to-treat analysis of RE-LY, the
double-blind double-dummy design in ROCKET AF is clearly
superior to the PROBE design in RE-LY. Furthermore, patients in
the ROCKET AF trial were significantly sicker as indicated by a
higher prevalence of congestive heart failure and hypertension as
well as substantially higher CHADS2 scores, rendering valid cross-
trial comparison of the two studies virtually impossible. Since both
trials compared the novel anticoagulant to warfarin, it would be
interesting to examine the comparison in matched subsets of
patients from each trial. The data required for such a comparison,
however, are not yet available. At this time, given the robust data
from RE-LY and ROCKET AF, both rivaroxaban and dabigatran
appear to be valid alternatives to warfarin.
Factors to consider when choosing an anticoagulant include
appreciation of the patient’s individual stroke and bleeding risks,
co-morbidities, compliance (once-daily dosing for rivaroxaban
compared to twice-daily dosing for dabigatran). It will be interest-
ing to compare the results when the other two trials of new orally
active FXa inhibitors which have completed enrolment (apixaban
in ARISTOTLE and edoxaban in ENGAGE-TIMI 48) become
available.
The low rate of bleeding events in patients on 110 mg bid dabi-
gatran etexilate in RE-LY imply that this dose could prove particu-
larly beneficial in patients judged to be at an increased risk for
bleeding, such as the elderly. With the denial of FDA approval of
this dosing regimen, however, the latter will not be an option, at
least in the USA, and it is currently unclear whether the European
Medicines Agency (EMEA) will follow the FDA’s course.
In patients ‘unsuitable’ for VKA treatment, apixaban has clearly
shown superiority when compared with the current practice of
aspirin treatment.67 However, as indicated above, ‘unsuitability’
for VKA treatment needs to be clearly defined, and the fraction
of patients unsuitable for a VKA, but suitable for the novel anticoa-
gulants, needs to be addressed. It is very likely that the other three
novel anticoagulants, although they have not yet been tested in this
patient population, will, like apixaban, be superior to aspirin.
Both rivaroxaban and dabigatran may be considered as alterna-
tives to warfarin for the treatment and prophylaxis of DVT and,
probably, VTE in general, given the robust results from
EINSTEIN-DVT42 and RECOVER.25 Furthermore, the impressive
reduction in events seen in the EINSTEIN-Extension trial42 may
result not only in the replacement of warfarin for the treatment
of VTE, but more importantly in a prolongation of the rec-
ommended duration of therapy.
Cost effectiveness
The use of novel anticoagulants for stroke prevention in AF or pro-
phylaxis and treatment of VTE will be substantially more expensive
than VKAs. Dabigatran, for example, is available in the USA at 20
times the cost of warfarin. However, these differences are reduced
by the lack of need for laboratory monitoring as well as the
improvement in clinical benefit for the novel anticoagulant. One
study has recently indicated the cost-effectiveness of dabigatran
when compared with warfarin for stroke prevention in AF.68
Also, since it is likely that the three other novel anticoagulants (riv-
aroxaban, apixaban, and edoxaban) will ultimately be approved to
prevent stroke and/or systemic embolism in AF, there may be
downward price pressure on the manufacturers of all four drugs.
Ultimately, carefully conducted analyses will be necessary to
define the patients in which these novel anticoagulants are
cost-effective.
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Conclusions
Data from recent large-scale Phase III trials add to the growing evi-
dence that VKAs will most likely be replaced by several novel antic-
oagulants which will improve substantially the management of
stroke prevention in AF, VTE prophylaxis and treatment, and poss-
ibly ACS. Awareness of the potential limitations of these drugs as
well as continuing research is indispensible for identifying the
characteristics of patients who should receive these agents, and
the relative advantages and disadvantages of each. It is likely that
the pages of this (and other) Heart journals will be filled with
articles and guidelines statements on the subject of this review.
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